世界卫生组织-全球抗癫痫运动中国农村癫痫示范项目结束后四年随访结果  

Follow-up study of the WHO-Global Campaign Against Epilepsy Demonstration Project in rural China after four years of its termination

作　　者：杨洪超[1] 王文志[1] 吴建中[1] 洪震[2] 戴秀英[3] 杨斌[4] 王太平 袁成林 马广玉 李世绰 

机构地区：[1]北京市神经外科研究所,100050 [2]复旦大学神经病学研究所,上海200040 [3]宁夏医科大学,银川750004 [4]河南省焦作市人民医院神经内科,454002 [5]山西省晋城市紧急医疗救援中心,048000 [6]江苏省扬州大学临床医学院附属医院神经内科,225001 [7]黑龙江省牡丹江市博爱老年医院,157000 [8]中国抗癫癎协会,北京100044

出　　处：《中国现代神经疾病杂志》2012年第5期530-535,共6页Chinese Journal of Contemporary Neurology and Neurosurgery

基　　金：国家卫生部与荷兰国家癫癎研究所(SEIN)合作项目~~

摘　　要：目的了解全球抗癫痫运动中国农村抗癫痫示范项目终止后4年曾接受苯巴比妥治疗的癫痫患者的远期治疗效果及转归，以为我国农村癫痫患者的防治和管理提供参考依据。方法2008年7—12月由经过培训的乡卫生院医师采用问卷与访谈相结合的形式入户调查，对原示范项目6省（市）共8个县经苯巴比妥治疗管理的2455例惊厥型癫痫患者进行随访。结果接受苯巴比妥治疗的2455例患者中共随访到1780例，其中939例（52．75％）继续服药，无发作和发作减少超过50％（有效）的患者于项目终止后的12、24、36和48个月时所占比例分别为66．77％（627／939）、68．37％（642／939）、71．35％（670／939）和73．06％（686／939）；841例（47．25％）停药患者中244例（29．01％）无发作、320例（38．05％）仍然发作但已停药、277例（32．94％）改用其他类型抗癫痫药物。对939例继续服用苯巴比妥与841例停药的癫痫患者进行疗效比较，继续服药者的远期疗效优于停药者（x2=12．423，P=0．002）。停药原因分别为发作停止（244例，29．01％）、改用其他抗癫痫药物（277例，32．94％）、未提供免费药物或无钱买药（93例，11．06％）、治疗效果欠佳（92例，10．94％）、当地买不到苯巴比妥（54例，6．42％）等。至2008年随访结束时共有206例患者死亡，标化死亡比达19．10；其中意外事故死亡为59例（28．64％），其次为脑血管病30例（14．56％）、癫痫持续状态窒息死亡28例（13．59％）。结论“全球抗癫痫运动”中国农村癫痫示范项目开展成功，远期治疗效果良好，值得进一步推广。癫痫人群死亡率高，尤其是意外事故死亡率高，值得引起注意。Objective To follow up the outcome of 2455 patients with epilepsy （the cohort） treated by phenobarbital （PB） during the WHO-Global Campaign Against Epilepsy Demonstration Project （GCAE/DP） in rural China after 4 years of its termination, to provide practical evidence for community control of epilepsy in rural China. Methods In 2008, the trained local township physicians, using a well-designed questionnaire, by door-to-door interview, followed up the cohort residents in 8 counties of 6 provinces where the GCAE/DP was conducted and completed for 4 years. Results One thousand seven hundred and eighty of the 2455 patients were visited in the follow-up study. Nine hundred and thirty-nine （52.75%） were still taking PB, the effectiveness rates （seizure free and seizure frequency reduced 〉 50%） among them at 12, 24, 36, 48 months after the GCAE/DP were 66.77% （627/939）, 68.37% （642/939）, 71.35% （670/939）, 73.06% （686/939）, respectively. In 841 patients （47.25%） who stopped taking PB, 244 eases （29.01%） were seizure free, 320 （38.05%） still had seizures but discontinued the treatment, 277 （32.94%） were treated by other antiepileptic drugs （AEDs）. Chi- square test was used to compare the therapeutic effectiveness in 939 patients continuing taking PB and 841 patients abandoning PB. Patients continuing taking PB had a better outcome than patients abandoning PB （X2= 12.423, P---0.002）. The main reasons of PB withdrawal were seizure free （29.01%）, taking other AEDs （32.94%）, no free drug or no money （11.06%）, effect was not good or PB was not available （6.42%）. Two hundred and six patients died between 2002 and 2008. The standardized mortality ratio （SMR） for the cohort was 19.10. The three leading causes of death were： accidents （n = 59, 28.64%）, eercbrovaseular diseases （n = 30, 14.56%） and status epilepticus （n = 28, 13.59%）. Conclusion The GCAE/DP was successful and with long term good results, so it is worthy for further promot

关 键 词：队列研究 干预性研究 随访研究 癫癎 苯巴比妥 死亡率 农村人口 中国 

分 类 号：R742.1[医药卫生—神经病学与精神病学]